Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990
摘要:
Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.
作者感谢西班牙国家科学与创新部长 (MICINN)(授权号 CTQ2007-65218)、Consolider Ingenio(授权号 2010-CSD-2007-00006 和 CTQ2011-24165)、Generalitat Valenciana(授权号为039)、Fondos Europeos para el Desarrollo Regional (FEDER) 和阿利坎特大学的财政支持。
Asymmetric Vinylogous Aza-Darzens Approach to Vinyl Aziridines
作者:Isaac Chogii、Pradipta Das、Michael D. Delost、Mark N. Crawford、Jon T. Njardarson
DOI:10.1021/acs.orglett.8b02074
日期:2018.8.17
A new asymmetric approach to assemble cis-vinyl aziridines is reported. A reaction of strategically substituted dienolates, decorated with a gamma-leaving group, with chiral sulfinimines afforded chiral vinyl aziridine products in good to excellent yields. This is the first systematic study toward the realization of a useful asymmetric vinylogous aza-Darzens reaction. The reaction is initiated by a syn-selective addition, affording cis-vinyl aziridine products after displacement of bromide. The low syn-diastereoselectivity is attributed to competing retro-Mannich pathways.